| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H23FN6O3 |
| Molecular Weight | 438.4548 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(F)=C(C=C2)C3=CC=C(CNCC4=CN=NN4)C=C3
InChI
InChIKey=BTTNOGHPGJANSW-IBGZPJMESA-N
InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1
| Molecular Formula | C22H23FN6O3 |
| Molecular Weight | 438.4548 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Radezolid (RX-1741) is a novel oxazolidinone antibiotic agent and is the first biaryloxazolidinone in clinical development. It is being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trialsfor the treatment of community-acquired pneumonia; uncomplicated skin and skin structure infections. The mechanism of action for this drug seems to be an inhibition of 50S ribosomal subunit.
Originator
Approval Year
Sourcing
Sample Use Guides
It was studied the mechanisms involved in radezolid accumulation in cells, using THP-1 macrophages as a model. Data were obtained after 2 h of incubation with 50 mg/liter radezolid. When cells were incubated at 4°C, the apparent cellular concentrations of radezolid decreased to about 35 to 40% of their control values. In parallel experiments, we observed that radezolid's accumulation was not modified by either ATP depletion or efflux pump inhibitors.
